Loading
  1. AcroCyte Therapeutics Inc
    AcroCyte Therapeutics is a cell-based precision medicine company. Our current focus lies in utilizing our core technology R3CE—rapid, reproducible, rare cell expansion— to assist clinical treatment and scientific research.
    Session
  2. AgenT
    AgenT is a French life sciences company on a mission to defeat Alzheimer's by targeting the silent phase.
    Session
  3. Aluda Pharmaceuticals
    Aluda was founded to reexamine how fundamental cell processes are altered by disease, combining rational drug design with holistic objectives to make wider impact.
    Session
  4. BioLattice Ophthalmics, Inc.
    We are addressing the need for tissue repair solutions, beginning with cornea.
    Session
  5. Black Canyon Bio (BCB) is developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAPTM) Technology platform.
    Session
  6. Celine Biotechnologies
    We are pioneering a novel approach by integrating proprietary synthetic biology methods and de novo protein designs with the power of generative AI to automate the discovery process and develop patient-tailored immune-mediated therapies at scale for Chronic and Age-Related diseases.
    Session
  7. CELLeBRAIN is an R&D biotechnology company specializing in the development of gene and cell therapy for the treatment of solid cancers, with a particular focus on glioblastoma multiforme (GBM).
    Session
  8. Cha Therapeutics, Inc
    Cha Therapeutics seeks to realize the untapped potential of immune checkpoint inhibitors (ICIs).
    Session
  9. Coastar Therapeutics Inc.
    Coastar Therapeutics is a venture-backed biotech company based in San Diego, CA focused on next generation gene delivery technology.
    Session
  10. CytoArm Co.,Ltd.
    CytoArm focuses on untreatable diseases through a next generation T cell therapy, Armed-T cell.
    Session
  11. Endure Biotherapeutics, Inc.
    Endure Biotherapeutics (“Endure Bio”®) is developing engineered engraftable live biotherapeutics for metabolic diseases by genetically engineering human native bacteria to express therapeutic compounds.
    Session
  12. Everfront Biotech
    The mission of Everfront Biotech is to address unmet medical needs by developing orphan drugs to treat some of the world's deadliest diseases, including high-grade gliomas and pancreatic cancer.
    Session
  13. FELIQS
    FELIQS is a clinical-ready stage company. The Company has a portfolio of two patent-protected drug product ophthalmology candidates.
    Session
  14. Fzata, Inc.
    Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform.
    Session
  15. GelSana Therapeutics, Inc.
    GelSana's novel polymers improve healing in impaired wounds, particularly in chronic wounds with high inflammation.
    Session
  16. Human Biome Institute
    HBI is a private company focused on developing cutting-edge Microbiome-Based Therapeutics.
    Session
  17. ImmunoShield Therapeutics seeks to enable the high-throughput biomanufacturing of hydrogel-based regenerative medicine products and the application of allogeneic cell products in the absence of chronic systemic immunosuppression.
    Session
  18. Incircular
    Incircular's mission is to advance Biotech and Pharma applications by effective stabilization of proteins using INCYPRO, a cutting-edge chemical protein engineering technology.
    Session
  19. Isosterix, Inc.
    Isosterix is developing a differentiated small-molecule inhibitor of Kat6A, an epigenetic oncogene which is amplified and implicated in multiple tumor types, including breast cancer.
    Session
  20. Jaan Biotherapeutics
    Jaan biotherapeutics is a pre-investigational new drug application company developing treatments that target microRNAs to regenerate heart muscle withing the heart and treat heart disease, the largest cause of death of man.
    Session
  21. KaloCyte, Inc.
    KaloCyte is a pre-clinical biotech therapeutic startup company developing ErythroMer, a bioengineered artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage.
    Session
  22. Keliomics, Inc.
    Keliomics is an emerging biotechnology company whose breakthrough platform for organ-scale biology preserves the full composition, structure, and function of primary human tissues.
    Session
  23. Leverna Therapeutics
    Leverna Therapeutics is a Boston-based preclinical RNA therapeutics company developing a portfolio of CNS-focused antisense oligonucleotide (ASO) programs.
    Session
  24. Lixa Pty Ltd
    Biotech company with the goal to solve the antimicrobial resistance pandemic for anyone, anything, anywhere.
    Session
  25. Longieva has been developing novel therapeutics for validated targets for CNS disorders with utility in neurodegeneration (such as Alzheimer's and Parkinson's) and addictive disorders.
    Session
  26. Mabswitch Inc
    Mabswitch Inc, is a leading biotechnology firm specializing in the development of regulatable immunotherapies based on the groundbreaking invention of affinity switches for antibodies.
    Session
  27. Matrubials Inc.
    Matrubials Inc. is developing milk-inspired therapeutics to address infectious diseases.
    Session
  28. Merlin has a pre-clinical mRNA-delivered immune activator with strong IP with in-vivo and human epi survival data in both pediatric ($100M PRV) and $2B adult markets.
    Session
  29. Mikrobiomik Healthcare Co. S.L.
    Founded in 2018 and headquartered in Derio (Bizkaia), Mikrobiomik is a bio-pharmaceutical company created to conduct research, develop and manufacture of medicines based on the human microbiome.
    Session
  30. Minutia
    Minutia is developing a regenerative medicine platform that improves safety and success outcomes of transplanted cells, our first therapy is a functional cure for Type 1 and Insulin Dependent Type 2 Diabetes with a simple outpatient procedure.
    Session
  31. NemaGen Discoveries
    NemaGen Discoveries is a New Jersey-based biotechnology company that is advancing therapies for patients suffering from allergic disorders and pulmonary fibrosis.
    Session
  32. Neuroene is developing mitochondrial-protective small molecules for epilepsy, Parkinson's and mitochondrial diseases.
    Session
  33. Neuronascent, Inc.
    Neuronascent Inc. discovers and develops novel neuron regenerative therapies for neurodegenerative and rare pediatric neurological diseases.
    Session
  34. Oligomerix Inc
    Oligomerix initiated 1st in human clinical trials in January, 2023 for its lead tau inhibitor of self-association which works at the beginning of the tau cascade to prevent tau aggregation.
    Session
  35. Oniria Therapuetics SL
    Oniria Therapeutics aims to revolutionize cancer treatment by bringing to market the first-in-class drug ONR-001, designed for solid and liquid aggressive tumors unresponsive to current treatments, paving the way for novel therapeutic combinations or standalone treatments.
    Session
  36. Orakl Oncology
    Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development.
    Session
  37. Origami Therapeutics, Inc.
    Origami Therapeutics is developing curative therapies that target and degrade disease-related proteins.
    Session
  38. Orlia
    Orlia provides optimization tools to maximize yield and improve cell health and viability in bioreactors and fermenters.
    Session
  39. Papillon Therapeutics, Inc.
    Papillon Therapeutics is a biotechnology company advancing genetic medicines for life threatening conditions with neurologic disease.
    Session
  40. PHIOGEN
    PHIOGEN is a spin-off from Baylor College of Medicine and was born out of innovation from the globally renowned team at TAILOR Labs, one of the US's only bacteriophage therapy centers, now being commercialized to combat the AMR infection crisis.
    Session
  41. SiNON Nano Sciences
    SiNON has developed a patented tunable carbon nanoparticle that acts as a ‘Trojan horse' drug delivery platform that allows drugs to cross the blood brain barrier to treat many different neurological diseases.
    Session
  42. SLAM Bio is a preclinical stage biotech company developing a platform of antibodies and antibody drug conjugates (ADCs) against signaling lymphocytic activation molecule (SLAM) protein family.
    Session
  43. Suntec Medical
    Suntec has a proprietary MINC (Multi-target Immune-modulation Nanocomplex) technology platform to develop highly effective and safe immunotherapies.
    Session
  44. Synergy Therapeutics Inc.
    Synergy Therapeutics Inc. has discovered and developed a novel and disruptive way to potently upregulate p53, the "guardian of the genome", in both wildtype and mutant cancer cells.
    Session
  45. Tachmed develops revolutionary, proprietary technologies designed to detect chronic and infectious diseases.
    Session
  46. Trust Bio-sonics Inc.
    Trust Bio-sonics Inc. is a Taiwan based pharmaceutic company (Private) and a world leader in microsphere technologies for contrast-enhanced ultrasound imaging and ultrasound-mediated drug delivery technologies.
    Session
  47. VoxCell BioInnovation
    VoxCell is creating human-like vascularized tissue models as a screening platform in drug development; by combining Canada's first high-resolution 3D bioprinter, VoxCell's proprietary universal bioinks and VoxCell's vascularization software.
    Session
  48. Vyro Bio Inc
    Vyro is a worldwide pioneer in the development of therapies and drug-delivery viral vectors based on Zika.
    Session

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS